Sensei Biotherapeutics (NASDAQ:SNSE) Issues Earnings Results

Posted by Geri Gentry on May 15th, 2026

Sensei Biotherapeutics (NASDAQ:SNSE – Get Free Report) announced its quarterly earnings data on Friday. The company reported ($131.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($130.83), FiscalAI reports.

Sensei Biotherapeutics Trading Up 3.1%

SNSE traded up $0.61 on Friday, hitting $20.43. The company had a trading volume of 40,624 shares, compared to its average volume of 223,122. The firm has a market cap of $27.40 million, a P/E ratio of -1.23 and a beta of -0.18. Sensei Biotherapeutics has a 1 year low of $5.25 and a 1 year high of $36.76. The company’s fifty day moving average price is $29.11 and its 200 day moving average price is $17.85.

Insider Transactions at Sensei Biotherapeutics

In related news, major shareholder Millennium Management Llc sold 8,151 shares of the business’s stock in a transaction dated Tuesday, April 7th. The shares were sold at an average price of $31.01, for a total value of $252,762.51. Following the sale, the insider directly owned 133,986 shares in the company, valued at approximately $4,154,905.86. The trade was a 5.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders have bought 46,980 shares of company stock valued at $1,341,669 and have sold 23,067 shares valued at $704,439. Company insiders own 23.20% of the company’s stock.

Institutional Trading of Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. Renaissance Technologies LLC boosted its stake in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE – Free Report) by 10.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 11,516 shares of the company’s stock after buying an additional 1,100 shares during the period. Renaissance Technologies LLC owned approximately 0.91% of Sensei Biotherapeutics worth $123,000 at the end of the most recent quarter. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics News Summary

Here are the key news stories impacting Sensei Biotherapeutics this week:

Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release

Analyst Upgrades and Downgrades

Several research analysts have recently commented on SNSE shares. Zacks Research upgraded Sensei Biotherapeutics to a “hold” rating in a report on Tuesday, April 21st. Leerink Partners started coverage on Sensei Biotherapeutics in a report on Monday, April 20th. They set an “outperform” rating and a $50.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Friday, April 24th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Sensei Biotherapeutics presently has an average rating of “Hold” and an average target price of $40.00.

Read Our Latest Report on Sensei Biotherapeutics

Sensei Biotherapeutics Company Profile

(Get Free Report)

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.